Clinical Trials

By targeting the physical mechanics of tumors rather than biochemical pathways, Myosin Therapeutics aims to conquer glioblastoma and court investors in NYC.

Cyrano Therapeutics reports positive Phase 2 data for a repurposed asthma drug to treat post-viral smell loss, but regulatory hurdles loom for Phase 3.

With positive Phase 3 data and an FDA review underway, a novel copper IUD aims to double its lifespan while navigating strict new provider safety mandates.

Virginia Cancer Specialists is expanding its Warrenton footprint, leveraging corporate infrastructure to decentralize clinical trials and ease patient burdens.

A $29 million gift to Sunnybrook Health Sciences Centre accelerates Canada's precision oncology race while highlighting a reliance on private wealth.

Merz completes Phase III migraine trial recruitment six months early, signaling a strategic threat to AbbVie’s dominance with its purified neurotoxin, XEOMIN.

Pilatus Biosciences doses its first Hong Kong patient with PLT012, signaling a strategic shift toward metabolic immunotherapies and Asian clinical hubs.

Parabilis Medicines advances its first-in-class beta-catenin inhibitor into a new FAP cohort, signaling a paradigm shift from surgical intervention to systemic prevention.

A new alliance between GCCL and LabConnect reveals how independent central labs are building global networks to challenge mega-CROs in clinical trial logistics.

Following its 2024 Sanofi spin-off, Inhibrx Biosciences is preparing to unveil pivotal cancer trial data that could validate its multivalent protein platform.

Suvoda’s Sofia AI moves beyond chatbot hype, executing complex clinical actions while maintaining the strict compliance required in healthcare R&D.

Trevi Therapeutics heads to CHEST 2026 with compelling patient-reported outcomes for its IPF chronic cough drug, aiming to fill a massive clinical void.

Immuron’s Phase 2 Travelan trial missed its primary endpoint, but a 71% drop in antibiotic use has the Pentagon and microbiome experts paying close attention.

New real-world data reveals a 34% drop in hospitalizations for heart failure patients using CCM therapy, bridging a crucial gap in cardiac care economics.

Odyssey Therapeutics is testing a novel combination therapy for ulcerative colitis, aiming to break the therapeutic ceiling that limits current IBD treatments.

For decades, severe acne treatments forced patients into a maze of antibiotics and harsh side effects. A new drug might finally change the system.

With new Phase 3 data for inactive thyroid eye disease, Innovent Biologics is solidifying a domestic moat against foreign biotech rivals in China.

A landmark 6,000-person trial by Holobiome and Radicle Science is utilizing AI and decentralized testing to see if food can solve anxiety.

Asahi Kasei Therapeutics begins Phase 2a trials for AIC468, a pioneering RNA-splicing therapy aiming to solve a critical kidney transplant dilemma.

CytoDyn is pivoting to oncology with its CCR5 inhibitor leronlimab. Upcoming Phase 2 data at ESMO 2026 could determine the biotech's financial survival.